Chinese biopharmaceutical company: Pegaspargase injection has been approved for market by the U.S. Food and Drug Administration.

China Biologic Pharmaceutical Co., Ltd. announced that the company's jointly developed Pembrolizumab Injection has been approved by the US Food and Drug Administration for marketing. It can be used in combination with cisplatin or carboplatin and 5-fluorouracil for first-line treatment of recurrent or metastatic non-keratinizing nasopharyngeal carcinoma in adults. It can also be used as a monotherapy for adult patients with metastatic non-keratinizing nasopharyngeal carcinoma who have experienced disease progression during or after platinum-based chemotherapy and have received at least one other previous therapy.